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Mark V. Sherrid, MD, Milla Arabadjian, NP, Anna Koulova, MDO n occasion, a study’s negative ﬁndingsovershadow its positive results, as in thereport from Coppini et al. (1) in this issue
of the Journal. In this study, the risk of sudden
cardiac death (SCD) in patients with hypertrophic
cardiomyopathy (HCM) as a result of thin-ﬁlament
mutations is no higher than in those with the more
prevalent thick ﬁlament mutations. Phenotypic dif-
ferences of thin-ﬁlament patients include more
frequent presentation with atypical concentric or api-
cal hypertrophy, less hypertrophy and resting left
ventricular (LV) outﬂow tract obstruction (19% vs.
34%), and increased predisposition to adverse LV
remodeling and heart failure.SEE PAGE 2589The discovery that mutations in genes coding for
sarcomeric proteins are associated with HCM (2)
profoundly altered our understanding of the condi-
tion, with long-term potential for disease mitigation
and prevention. Genotype analysis is clinically in-
dicated to identify family members with inherited
mutations who are at risk for HCM, a class IIa
recommendation in recent guidelines (3).
Most genotyped HCM patients have mutations
in thick ﬁlament genes: myosin heavy chain (MYH7)
and myosin binding protein C (MYBPC3) (4–9).
Mutations in the remaining thick ﬁlament genes,
encoding regulatory (MYL2) and essential (MYL3)
myosin light chains, are quite rare. A minority of HCM
patients carry thin-ﬁlament gene mutations in cardiac
troponin-T (TNNT2) and I (TNNI3), a-tropomyosin*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the Hypertrophic Cardiomyopathy Program, Mount Sinai Roosevelt
and St. Luke’s Hospitals, Icahn School of Medicine at Mount Sinai, New
York, New York. The authors have reported that they have no relation-
ships relevant to the contents of this paper to disclose.(TPM1), and cardiac actin (ACTC) (4–9). A meta-
analysis (5) found thin-ﬁlament mutations in an
average of 6% of HCM patients (range 2.2 to 10.5%);
TNNT2 was the most common, found in an average of
2.7% of HCM patients (range 0 to 6.5%) (4–9). Because
of their shared geography in the sarcomere and func-
tion, thin-ﬁlament mutations are considered together.
SCD incidence in HCM patients is approximately
1%/year (10), but occurs at a relatively young age
(average 42 years). Life expectancy may otherwise
be normal, underscoring the clinical importance
of early recognition and primary prevention. Risk
stratiﬁcation is challenging owing to the low event
rate, low positive predictive accuracy for individual
risk factors (10% to 20%, at most), and the ambiguity
inherent in clinical criteria (3). Substantial attention
has focused on this clinical issue because of the
option of the implantable cardioverter-deﬁbrillator
(ICD), with its life-saving beneﬁts and attendant
risks (3,11–14). Thus, the discovery of HCM-associated
mutations raised hopes that their deﬁnition would
contribute to SCD risk stratiﬁcation.
Early genotype-natural history analyses of a
limited number of families initially placed thin-
ﬁlament mutations high on the list of potentially
malignant genotypes. There was particular concern
that patients with troponin mutations might have
high SCD risk, but doubt was cast by subsequent an-
alyses of the natural history of patients with troponin
mutations and family members (many certainly car-
rying these mutations). Ackerman et al. found no
sudden deaths in family histories of referred HCM
outpatients with troponin-T mutations (15). Another
study showed a 0.9%/year SCD rate for individuals
carrying a troponin-T mutation; however, the ma-
jority of these individuals were relatives without
hypertrophy, who might be expected to have a more
benign prognosis (16).
Coppini et al. (1) compare prognoses in pa-
tients with HCM phenotype: 80 with thin-ﬁlament
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2602mutations (67 with troponin mutations) and 150 with
thick ﬁlament mutations. After 4.7 years, the 2 groups
had similar malignant ventricular arrhythmias and
SCD rates (p ¼ 0.59). The thin-ﬁlament HCM group
had 1 sudden death and 10 aborted potentially lethal
arrhythmias (total 13.8%). In comparison, the thick
ﬁlament-HCM group had 9 sudden deaths and 8
aborted potentially lethal arrhythmias (total 11.3%).
There was no difference in mortality during the 4.7
years of follow-up. Thus, thin-ﬁlament mutations
were no more malignant for SCD than thick ﬁlament
mutations. Importantly, SCD risk does not solely
depend on thin-ﬁlament genotype; thus, ICD place-
ment is not appropriate in HCM patients solely
because a thin-ﬁlament mutation is detected. These
patients’ risk must be judged by conventional risk
stratiﬁcation. This remains the largest unresolved
clinical challenge for HCM patients and their physi-
cians (3,11–14).
HEART FAILURE RISK AND
THIN-FILAMENT MUTATIONS
There were important differences between the thin
and thick-ﬁlament HCM groups in the incidence of
heart failure symptoms and adverse LV remodeling.
Despite less LV thickening and resting LV outﬂow
tract obstruction at presentation, thin-ﬁlament HCM
patients more frequently developed severe heart
failure symptoms (19% vs. 10%), atrial ﬁbrillation,
adverse remodeling with ejection fraction less than
50%, or a restrictive diastolic echocardiographic
pattern (29% vs. 11%).
As Coppini et al. (1) describe, progressive heart
failure and disability affect a minority of HCM pa-
tients. However, disability at a relatively young age
has drawn considerable attention to its manage-
ment. Excellent treatment options are available for
obstructed HCM patients, including advanced phar-
macological therapy (17,18) and septal reduction,
preferentially with surgical septal myectomy (3).
Nonobstructed patients with severe symptoms and
preserved ejection fraction (19) have fewer options;
pharmacotherapy with b-blockade and verapamil is
less effective for symptom relief. Low-dose diuretics
are applied for pulmonary congestion. Spironolactone
is ineffective to mitigate ﬁbrosis (20). Nonobstructed
patients with severe symptoms and declining ejection
fraction have similarly scanty options; patients
receive the same therapy as those with dilated car-
diomyopathy (angiotensin-converting enzyme inhib-
itor, angiotensin receptor blocker, b-blockade)
including transplantation for the end stage (21,22).
Severely symptomatic patients with preservedejection fraction may rarely require transplantation
because of a small diastolic LV cavity volume and
consequently decreased stroke volume (19,23).
TREATMENT BENEFIT WILL DEPEND ON
PENETRANCE AND DISEASE EXPRESSION
Is delay or prevention of adverse LV remodeling
and heart failure possible? The glacially slow devel-
opment of hypertrophic phenotype and ﬁbrosis in
HCM is daunting. Novel approaches were adopted to
design a trial of a pharmacological therapy when
the phenotype may develop over decades (24). The
utility of preventive therapy and genotype analysis
depends on relatively high penetrance and expres-
sivity of the HCM phenotype, but their extent is
uncertain.
HCM’s autosomal dominant inheritance pattern
was revealed in the 1970s by widespread application
of echocardiography in patients’ families (25–27). A
parent of the index case usually manifested asym-
metric hypertrophy, suggesting high penetrance by
adulthood. Early studies suggested frequent con-
version to positive phenotype in adolescence; 5 of
16 initially normal adolescent offspring of HCM
patients exhibited thickening after an average of 4
years (28). However, HCM research previously suf-
fered from selection and ascertainment bias, and
families in early reports were among the most ill
(10), and might not be representative. The recent
longitudinal study by Jensen et al. (29) showed only
6% penetrance of hypertrophy in children after
12 years. Similarly, Pasquale et al. (16) showed a
17% conversion rate from normal to hypertrophy in
adults and children after greater than 6 years. In the
Framingham and Jackson studies, sarcomeric gene
variants identiﬁed in the general population had
less than the predicted effect in clinically identiﬁed
families (30). Of 3,600 adult individuals older than
50 years, 22 had conﬁrmed pathogenic HCM-related
mutations, but only 4 met diagnostic criteria. This
indicates more genetic complexity, including as yet
undiscovered variants, and epigenetic or environ-
mental modiﬁers that may be crucial for expression
of known sarcomeric mutations. It now seems timely
for a large, multicenter, longitudinal study, similar to
that by Jensen et al. (29), focusing on penetrance
and disease expression in the gene-positive children
detected during the past 20-plus years. Such data
would be essential for planning clinical trials and
should answer key clinical questions: What is the
chance of developing thickening and when? What
is the chance of developing disabling HCM sym-
ptoms and risk (31)? Cost-beneﬁt analysis indicated a
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2603reasonable expense for genotype analysis, compared
with conventional echocardiographic and electrocar-
diographic screening (32). However, beneﬁt highly
depends on penetrance and expression, which are
not yet adequately deﬁned.ICD PROGRAMMING AND EVENT RATES
An apparently unavoidable pitfall of many SCD
studies has been use of “appropriate ICD discharge”
as an endpoint equivalent of SCD. Programming ICDs
to only discharge at heart rates greater than 200
beats/min or after delay decreases discharges that
were previously counted as SCD equivalents (33). An
ICD’s presence may create a self-fulﬁlling prophecy.
It is inserted for perceived risk; when it discharges
there is conﬁrmation of the perception of risk, even
if the discharges are not always equivalent to SCD.
There is little way around this limitation when
research is conducted in a real-world environ-
ment. Going forward, programming according to
the Multicenter Automatic Deﬁbrillator Implantation
Trial-Reduce Inappropriate Therapy proved recom-
mendations and scrupulous vetting of discharges by
a central electrophysiology laboratory are essential.NOVEL MARKERS OF RISK
CMR ﬁbrosis correlates with heart failure develop-
ment (34); its use to predict SCD seems promising
(35). Biomarkers, including serum high-sensitivity
troponin-T and B-type natriuretic peptide, correlate
with heart failure development and cardiovascular
mortality (36–40). Which biomarkers, including ge-
notype, are the most sensitive and speciﬁc for adverse
remodeling and heart failure prognosis, and whether
they detect the same patients, remains to be seen.
Recognition of the limitations and equipoise of
clinical risk stratiﬁcation for HCM outcomes (3,11–14)
has led to initiation of a 2,750-patient 5-year inter-
national, observational trial (41) to assess effects of
CMR ﬁbrosis (both delayed enhancement and T1),
genotype, and biomarkers (including high-sensitivity
troponin, B-type natriuretic peptide, and collagen
turnover). For HCM patients, the pieces of the prog-
nostic puzzle are falling into place.
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